HK Stock Market Move | Cofoe Medical Technology (01187) surged over 10%, with respiratory support becoming the main growth engine and AI and ecosystem collaboration accelerating their implementation.

Cofoe Medical Technology (01187) surged over 10%, up 10.4% as of press time, at HK$30.16, with a turnover of HK$47.4147 million. On the news front, in the first half of this year, Cofoe Medical Technology achieved operating revenue of RMB 2.072 billion, up 38.51% year-on-year; net profit attributable to shareholders of RMB 202 million, up 20.84% year-on-year; and non-GAAP net profit of RMB 173 million, up 26.73% year-on-year. In the first half, revenue from the company's top five single products grew 50% year-on-year. By segment, respiratory support revenue was RMB 267 million, up 166.90% year-on-year, with self-developed ventilator sales exceeding RMB 100 million in the second quarter alone. Zhongtai previously noted that the company established an artificial intelligence research institute to advance the development of the Cofoe large model, and completed engineering validation of on-device intelligent algorithms with ventilators as the first application scenario; the new-generation AI ventilator C11 was officially launched. The CGM independently developed by its associate company Shenzhen Cofoe Biotechnology has obtained a Class III medical device registration certificate, and two blood glucose monitoring systems have obtained EU IVDR certification. The company partnered with Tencent Tianlai Laboratory to launch the bone conduction hearing aid X5, with the first batch of 17 products across 5 major categories integrated into the HarmonyOS ecosystem, and has established production lines for Royal Philips brand blood pressure monitors, blood glucose meters, pulse oximeters, thermometers, and other products.